Comparisons

Research indicates that Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to Semaglutide, a GLP-1-only agonist, in head-to-head clinical trials. The S

Retatrutide, a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, demonstrates unprecedented weight loss efficacy in clinical trials, up to 24.2% body weight r

Retatrutide's triple receptor mechanism (GLP-1/GIP/Glucagon) achieves significantly greater weight loss than Semaglutide's single GLP-1 pathway, 24.2% vs 14.9% body weight reduction in clinical trials.

AOD-9604, a modified fragment of human growth hormone (amino acids 176-191), and Semaglutide, a GLP-1 receptor agonist, represent fundamentally different approaches to fat metabolism research. AOD-960

BPC-157 is the better-supported choice in animal data for gut, tendon and ligament, and oral-stability research; TB-500 (and its parent thymosin β-4) is the better-supported choice for cell migration,

Semax and Selank, both developed in Russia for clinical use, represent complementary approaches to cognitive and emotional regulation through peptide therapeutics. Semax, derived from ACTH (4-10), pri

Ipamorelin starts the GH pulse at the ghrelin receptor (~2-hour half-life); in the rat and swine study that introduced it (PMID 9849822) it released GH without the ACTH and cortisol rise seen with GHR

Epithalon and FOXO4-DRI represent two distinct approaches to cellular anti-aging research. Epithalon, a synthetic tetrapeptide based on pineal gland epithalamin, activates telomerase to maintain or ex

GHK-Cu and BPC-157 are two of the most researched peptides for tissue repair, with distinct but potentially complementary mechanisms. GHK-Cu, a naturally occurring copper-binding tripeptide, excels in

GHRP-6 and GHRP-2 are both hexapeptide growth hormone releasing peptides that stimulate GH release through the ghrelin receptor (GHS-R1a), but differ significantly in selectivity and side effect profi

Sermorelin and CJC-1295 are both GHRH analogs that stimulate pituitary GH release through the GHRH receptor, but differ dramatically in pharmacokinetics. Sermorelin is the natural GHRH (1-29) fragment

Hexarelin and Ipamorelin represent opposite ends of the GHRP spectrum: maximum potency versus maximum selectivity. Hexarelin is the most potent GHRP for acute GH release but carries significant off-ta

BPC-157 and KPV represent different approaches to tissue healing and inflammation control, with overlapping applications in gastrointestinal research. BPC-157, a stable gastric pentadecapeptide, promo

Semaglutide demonstrates superior weight loss efficacy compared to Liraglutide in both clinical trial data and head-to-head comparisons, with once-weekly Semaglutide 2.4 mg (Wegovy) producing approxim

Thymosin Alpha-1 and LL-37 are two well-characterized immune-modulating peptides with complementary but distinct mechanisms. Thymosin Alpha-1 is a thymic hormone that primarily modulates adaptive immu

Ipamorelin is a selective GHRP (ghrelin receptor) with a ~2-hour half-life; in rats and swine it produced a GH pulse without the ACTH and cortisol rise seen with GHRP-6 and GHRP-2 (PMID 9849822). Serm

Epithalon and Thymosin Alpha-1 represent distinct but complementary approaches to age-associated decline. Epithalon is a pineal tetrapeptide studied for telomere elongation and telomerase activation;

PT-141 (Bremelanotide) and Melanotan II are both cyclic heptapeptide analogs of alpha-MSH acting on melanocortin receptors, but with different selectivity profiles and regulatory status. PT-141 receiv

Tirzepatide and CagriSema (cagrilintide + semaglutide) represent two distinct multi-receptor approaches to obesity pharmacotherapy. Tirzepatide's SURMOUNT-1 trial achieved 22.5% body weight loss at th

Semax and Dihexa are two of the most potent cognitive-enhancing peptides in preclinical research, though through entirely different mechanisms. Semax is an ACTH(4-7) analog registered in Russia that s

GHK-Cu and Epithalon are two well-characterized anti-aging peptides targeting different biological mechanisms. GHK-Cu is a naturally occurring copper tripeptide that modulates gene expression, promote

BPC-157 and LL-37 are both studied for wound healing but through distinct mechanisms: BPC-157 promotes tissue repair through angiogenesis, fibroblast activation, and nitric oxide modulation; LL-37 pro

BPC-157 and Ipamorelin target entirely different physiological systems: BPC-157 is a tissue repair peptide derived from gastric juice that promotes healing through angiogenesis and fibroblast activati

Semax and PT-141 share ACTH/alpha-MSH origin but represent pharmacologically distinct agents. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analog registered in Russia as a cognitive and neuropr

Dihexa and Cerebrolysin both target cognitive enhancement and neuroprotection, but they occupy fundamentally different positions on the evidence spectrum. Dihexa is a small peptidomimetic reported to

FOXO4-DRI and MOTS-c represent two fundamentally different approaches to biological aging, targeting distinct hallmarks of the aging process. FOXO4-DRI is a senolytic peptide, a D-retro-inverso pepti

CJC-1295 with DAC and Mod GRF 1-29 (sold as CJC-1295 no DAC) are the same tetrasubstituted GRF(1-29) core; the only difference is the DAC linker, which extends half-life from minutes to 5.8–8.1 days.

Ipamorelin and GHRP-2 (pralmorelin) are both growth hormone secretagogues acting through the ghrelin receptor (GHSR-1a), but they sit at opposite ends of the class's selectivity spectrum. Ipamorelin w

TB-500 and GHK-Cu are both studied for tissue repair, but they represent two different biological strategies. TB-500 is a synthetic fragment modeled on Thymosin Beta-4 (Tβ4), a 43-amino-acid G-actin-s

Retatrutide and CagriSema are the two leading candidates to succeed GLP-1 monotherapy in obesity pharmacology, built on opposing design philosophies. Retatrutide is a single engineered peptide activat

Tesamorelin is an FDA-approved GHRH analog (Egrifta) with Phase 3 evidence: in a pooled analysis of two 26-week trials in 806 antiretroviral-treated HIV patients with excess abdominal fat, 2 mg daily

Tesamorelin is an FDA-approved GHRH analog with Phase 3 evidence that 2 mg daily reduced visceral adipose tissue 15.4% versus placebo at 26 weeks in 806 HIV-infected patients, sparing abdominal subcut

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial 12S rRNA that, in mice, activates AMPK-linked metabolic programs and prevents diet-induced obesity and insulin resistance (PMID: 25738459). H

PT-141 (bremelanotide, Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women on the basis of two Phase 3 RECONNECT trials (1,267 randomized): subc